Pharma Majors Face 'Patent Cliff'
Multinational pharmaceutical companies face significant declines in revenue when the patents on their best-selling drugs expire, allowing for the diffusion of cheaper copies. BMI identifies two companies as particularly vulnerable to generic competition in 2014; Teva Pharmaceuticals based in Israel and Britain's AstraZeneca Plc. We look at what generic competition means for these two firms as well as for the industry as a whole. This podcast features Pharmaceutical & Healthcare analyst Asif Ashraf.